Condition Lookup
Sub-Category:
Osteoporosis
Number of Conditions: 3
Postmenopausal Osteoporosis
Specialty: Diabetes and Endocrinology
Category: Bone and Mineral Metabolism Disorders
Sub-category: Osteoporosis
Symptoms:
fractures from minor trauma (e.g., hip, wrist, vertebral); back pain; loss of height; stooped posture
Root Cause:
Decreased estrogen levels after menopause lead to accelerated bone resorption, reducing bone density and increasing fracture risk.
How it's Diagnosed: videos
Bone Mineral Density (BMD) testing using dual-energy X-ray absorptiometry (DEXA), clinical assessment of risk factors, and evaluation for fragility fractures.
Treatment:
Lifestyle modifications (calcium and vitamin D supplementation, weight-bearing exercises), anti-resorptive medications (e.g., bisphosphonates), and anabolic therapies (e.g., teriparatide).
Medications:
Bisphosphonates (e.g., alendronate , risedronate ) to inhibit bone resorption; selective estrogen receptor modulators (e.g., raloxifene ) for estrogen mimicry; denosumab (RANK ligand inhibitor); teriparatide (parathyroid hormone analog for bone building); and calcitonin .
Prevalence:
How common the health condition is within a specific population.
Affects approximately 20% of postmenopausal women globally, with higher prevalence in individuals of European and Asian descent.
Risk Factors:
Factors or behaviors that increase the likelihood of developing the condition.
Advanced age, early menopause, low body weight, family history of osteoporosis, smoking, excessive alcohol intake, physical inactivity, and inadequate calcium/vitamin D intake.
Prognosis:
The expected outcome or course of the condition over time.
With early diagnosis and treatment, fracture risk can be significantly reduced, and quality of life preserved. Without treatment, progressive bone loss may lead to frequent fractures and disability.
Complications:
Additional problems or conditions that may arise as a result of the original condition.
Fractures, particularly of the hip and spine, which can lead to chronic pain, loss of independence, and increased mortality.
Glucocorticoid-Induced Osteoporosis
Specialty: Diabetes and Endocrinology
Category: Bone and Mineral Metabolism Disorders
Sub-category: Osteoporosis
Symptoms:
bone pain; increased susceptibility to fractures; height loss; muscle weakness
Root Cause:
Chronic glucocorticoid use reduces osteoblast activity and increases bone resorption, resulting in decreased bone formation and loss of bone mass.
How it's Diagnosed: videos
Assessment of bone density via DEXA scan, history of long-term glucocorticoid use, and clinical evaluation of fracture risk.
Treatment:
Minimizing glucocorticoid dosage when possible, supplementation with calcium and vitamin D, use of bisphosphonates or denosumab to reduce bone resorption, and anabolic therapies such as teriparatide for severe cases.
Medications:
Bisphosphonates like alendronate or zoledronic acid to reduce bone turnover; denosumab (a RANKL inhibitor) to prevent resorption; and teriparatide (a parathyroid hormone analog) to stimulate bone formation. Calcium and vitamin D are essential for all patients.
Prevalence:
How common the health condition is within a specific population.
Up to 30-50% of patients on long-term glucocorticoids develop significant bone loss; higher rates in older adults and postmenopausal women.
Risk Factors:
Factors or behaviors that increase the likelihood of developing the condition.
Long-term use of glucocorticoids, low body weight, advanced age, previous fractures, smoking, alcohol consumption, and low calcium/vitamin D intake.
Prognosis:
The expected outcome or course of the condition over time.
Early intervention can prevent fractures, but untreated cases carry a high risk of recurrent fractures and long-term disability.
Complications:
Additional problems or conditions that may arise as a result of the original condition.
Fragility fractures, particularly in the spine and ribs, leading to chronic pain, deformity, and impaired mobility.
Secondary Causes of Osteoporosis (e.g., Hyperthyroidism)
Specialty: Diabetes and Endocrinology
Category: Bone and Mineral Metabolism Disorders
Sub-category: Osteoporosis
Symptoms:
bone pain; fractures from minimal trauma; muscle weakness; height loss; fatigue
Root Cause:
Secondary osteoporosis results from an underlying medical condition (e.g., excess thyroid hormone in hyperthyroidism), which accelerates bone resorption and decreases bone strength.
How it's Diagnosed: videos
Identification of the underlying condition through blood tests (e.g., thyroid hormone levels, parathyroid hormone levels), DEXA scan to measure bone density, and evaluation for fragility fractures.
Treatment:
Treating the underlying cause (e.g., controlling hyperthyroidism with antithyroid medications or surgery), calcium and vitamin D supplementation, and using anti-resorptive agents like bisphosphonates if indicated.
Medications:
Bisphosphonates for bone preservation; treatment for the underlying cause (e.g., methimazole for hyperthyroidism or cinacalcet for hyperparathyroidism). Calcium and vitamin D are adjunct therapies.
Prevalence:
How common the health condition is within a specific population.
Varies depending on the underlying condition; hyperthyroidism-induced bone loss is common in individuals with untreated or poorly managed thyroid disease.
Risk Factors:
Factors or behaviors that increase the likelihood of developing the condition.
Presence of underlying medical conditions like hyperthyroidism, hyperparathyroidism, malabsorption syndromes, and chronic inflammatory diseases.
Prognosis:
The expected outcome or course of the condition over time.
Prognosis improves significantly with successful management of the underlying condition and preventive measures for bone health.
Complications:
Additional problems or conditions that may arise as a result of the original condition.
Increased fracture risk, chronic pain, spinal deformities, and reduced quality of life.